New drug combo tested for Tough-to-Treat cancers
NCT ID NCT07494435
Summary
This study is testing a new drug, WGI-0301, given together with an existing immunotherapy drug called nivolumab. It aims to see if this combination is safe and shows early signs of helping people with advanced liver cancer or advanced kidney cancer that has stopped responding to standard treatments. The trial will enroll about 230 participants at several hospitals to measure how well the tumors shrink and how long the treatment keeps the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
Shanghai, Shanghai Municipality, 200131, China
Conditions
Explore the condition pages connected to this study.